

Available online on 15.2.2025 at <http://ajprd.com>

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-24, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Review Article

Innovative Drug Delivery Systems: The Role of Dendrimers

Londhe Punam D*, Fugate Ajay, Vijay Shinde, Akshay Sadule, Komal Jadhav

Department of Pharmaceutics Shivlingeshwar College of Pharmacy, Almala Dist. Latur-413520, Maharashtra (MH), India

ABSTRACT

Dendrimers, highly branched and monodisperse macromolecules, have emerged as promising nanocarriers for drug delivery due to their unique structural and physicochemical properties. This review highlights the fundamental aspects of dendrimers, including their architecture, synthesis methods, and mechanisms of drug delivery. Dendrimers' internal cavities allow drug encapsulation, while their surface functional groups facilitate covalent conjugation and targeted delivery. Various types of dendrimers, such as PAMAM, PPI, and PEGylated dendrimers, offer versatility in addressing challenges like poor solubility, controlled release, and biocompatibility. The integration of dendrimers into modern drug delivery systems has opened avenues for precision medicine and enhanced therapeutic outcomes. This review aims to provide a comprehensive understanding of dendrimers and their potential in advancing drug delivery technologies.

Keywords: Dendrimers, drug delivery, PAMAM dendrimers, nanocarriers, encapsulation, surface modification.

ARTICLE INFO: Received 14 Nov.2024; Review Complete 26 Dec. 2024; Accepted 23 Jan. 2025.; Available online 15 Feb. 2025



Cite this article as:

Londhe PD, Fugate A, Shinde V, Sadule A, Jadhav K, Innovative Drug Delivery Systems: The Role of Dendrimers, Asian Journal of Pharmaceutical Research and Development. 2025; 13(1):195-203, DOI: <http://dx.doi.org/10.22270/ajprd.v13i1.1527>

*Address for Correspondence:

Londhe Punam D, Department of Pharmaceutics Shivlingeshwar College of Pharmacy, Almala Dist. Latur-413520, Maharashtra (MH), India

INTRODUCTION

Dendrimers are a unique class of macromolecular compounds characterized by a highly branched, symmetrical structure radiating from a central core. These nanoscale structures exhibit precise architecture, with a defined size, shape, and functional groups at the periphery, making them ideal candidates for advanced drug delivery systems. The term "dendrimer" is derived from the Greek words dendron (tree) and meros (part), emphasizing their tree-like branching structure.⁽¹⁾ As early as 1978, Buhleir and coworkers synthesized and Early dendritic polymers were identified as the earliest "cascade" and "nonskid-chain-like" molecules with molecular cavity topologies. Donald A. Tomalia and his colleagues at the Dow Laboratories made significant progress in the creation of dendrimers between 1979 and 1985. According to Tomalia, they created dendrimers, which are polymers with a central, hollow core and tendrils that branched forth, one from another, in a precise, predictable way. The early history of dendrimers was influenced by these two scientific communities. The so-called polyamidoamine dendrimers, or PAMAM dendrimers, are a novel family of dendrimers based on a combination of amines

and amides that were first described by Tomalia et al. in 1983. New dendrimer designs are still being developed, and several other dendrimer designs were reported by different research groups in the 1980s and 1990s.

Dendrimers constitute nowadays a major field of research that has already generated about 20,000 publications. Dendrimers are constituted of repeating units, like polymers, but they largely differ from classical polymers by two main characteristics: i) they are never synthesized by polymerization reactions but step-by-step, affording a perfectly defined and highly reproducible structure, and ii) they have a highly branched 3-D architecture due to the use of at least one type of branching units as building blocks for their synthesis. The architecture of dendrimers, which are globular, nanoscale (1–100 nm) macromolecules, is composed of three distinct domains: (i) a core at the center of the dendrimer that is made up of an atom or molecule with at least two identical chemical functions; (ii) branches that emanate from the core and are made up of repeat units with at least one branch junction, whose repetition is organized in a geometrical progression that results in a series of radially concentric layers known as "generations"; and (ii) numerous

terminal functional groups that are typically found at the surface of dendritic architecture.

Drug delivery systems aim to enhance the therapeutic index of drugs by improving their bioavailability, targeting efficiency, and reducing side effects. Among these systems, dendrimers stand out due to their ability to encapsulate hydrophobic drugs within their internal cavities or conjugate hydrophilic drugs to their surface functional groups. These dual capabilities, along with their nanosize and tunable properties, make them versatile carriers for a wide range of drugs, including small molecules, peptides, and nucleic acids.^(2,3)

Dendrimers offer several advantages over conventional drug delivery systems, such as liposomes, micelles, and polymer-drug conjugates. Their monodispersity, high drug-loading capacity, and potential for surface modification enable targeted and controlled drug release. This reduces systemic toxicity and enhances therapeutic outcomes.⁽⁴⁾ Moreover, advancements in dendrimer chemistry have expanded their applications beyond drug delivery to diagnostics, gene therapy, and vaccine delivery.⁽⁵⁾ However, the clinical use of dendrimers faces challenges, including toxicity, high production costs, and potential immunogenicity. Research efforts are focused on developing biocompatible and cost-effective dendrimer formulations to overcome these limitations and harness their full potential.⁽⁶⁾




Figure 1: Structure of Dendrimer

STRUCTURAL FEATURES OF DENDRIMERS

Dendrimers are highly ordered macromolecules with a unique three-dimensional structure that distinguishes them from other polymers. Their architecture consists of three main components: the core, branching units, and terminal functional groups

Core

The core of a dendrimer acts as the central point from which the branching begins. It can be a single atom or a small molecule containing multiple reactive sites. The choice of the core significantly influences the dendrimer's size, shape, and properties. Common cores include ethylenediamine and pentaerythritol.⁽⁷⁾

Branching Units

Branching units are repetitive monomeric units radiating outward from the core in a highly symmetrical manner. Each layer of branching is referred to as a "generation." For example, a first-generation dendrimer (G1) has one layer of branches, while higher generations (e.g., G2, G3) have successive layers. The number of branches increases exponentially with each generation, resulting in a dense outer surface and a hollow interior.⁽⁸⁾

Terminal Functional Groups

The terminal groups are located at the surface of the dendrimer and determine its physicochemical properties, such as solubility, reactivity, and biocompatibility. Functional groups like amines, hydroxyls, and carboxyls can be chemically modified to achieve desired interactions with drugs or biological systems. For instance, cationic amine groups can facilitate interaction with negatively charged DNA or cell membranes.⁽⁹⁾




Figure 2: Structural Features Of Dendrimers

Key Structural Features

1. Monodispersity: Dendrimers have a uniform size and molecular weight due to controlled synthesis, unlike conventional polymers.
2. Nanoscale Dimensions: Dendrimers typically range from 1 to 10 nm, making them suitable for nanomedical applications.
3. High Functional Density: The number of terminal groups increases with generation, enabling high drug-loading capacity or multiple conjugation sites.⁽¹⁰⁾

4. Internal Cavities: The interior of a dendrimer contains void spaces that can encapsulate hydrophobic drugs, enhancing their solubility and stability.

SYNTHESIS OF DENDRIMERS:

Dendrimers are synthesized using two primary methods:

Divergent Method: Initiated from the core and grows outward through successive addition of branching units. This method ensures a well-defined structure but is time-intensive.




Figure 3: Divergent Method

Convergent Method: Begins at the periphery and proceeds inward toward the core. It reduces structural defects and provides better control over surface functionality.⁽¹¹⁾




Figure 4: Convergent Method

UNIQUE PROPERTIES OF DENDRIMERS

Dendrimers possess several distinctive physicochemical and biological properties that make them valuable for drug delivery applications. These properties stem from their well-defined structure, nanoscale size, and multifunctional surface.

1. High Degree of Branching

Dendrimers are hyperbranched macromolecules with a perfectly symmetrical and ordered structure. This high degree of branching ensures uniformity in molecular weight, size, and shape, which is crucial for predictable behavior in drug delivery applications. The controlled

branching also contributes to their high surface area and reactivity.⁽¹²⁾

1. Monodispersity

Unlike traditional polymers, which exhibit polydispersity (a mix of molecular weights), dendrimers are monodisperse, meaning all molecules in a batch have the same size and weight. This uniformity allows precise control over their interactions with drugs and biological systems, leading to more predictable pharmacokinetics and pharmacodynamics.⁽⁹⁾

2. Nanoscale Size and Shape

Dendrimers typically have a size range of 1–10 nm, depending on the generation. Their size is comparable to biological molecules such as proteins, enabling efficient interaction with cellular and subcellular structures. The globular shape of dendrimers allows them to penetrate biological membranes and accumulate at targeted sites.⁽⁶⁾

5. Multivalency and Surface Functionality

The numerous terminal functional groups on the dendrimer surface enable multiple drug molecules, targeting ligands, or imaging agents to be attached simultaneously. This multivalency enhances drug-loading capacity and facilitates targeted delivery to specific tissues or cells. Additionally, surface modification can improve solubility, stability, or biocompatibility of the dendrimer.⁽¹³⁾

6. Tunable Interior and Surface

Dendrimers have an internal cavity capable of encapsulating hydrophobic drugs, improving their solubility and stability. The surface groups can be tailored to control the release rate of drugs or to target specific cell types. This dual functionality (encapsulation and conjugation) allows dendrimers to deliver a wide variety of therapeutic agents, including hydrophilic and hydrophobic drugs.⁽¹⁴⁾

7. Enhanced Solubility and Bioavailability

By encapsulating poorly water-soluble drugs, dendrimers can improve their solubility and, consequently, their bioavailability. This property is especially useful for drugs with low therapeutic efficacy due to poor absorption.⁽²⁾

8. Biocompatibility

Many dendrimers, such as PEGylated and hydroxyl-terminated dendrimers, exhibit low toxicity and good biocompatibility. These properties can be further improved through surface modifications, making them suitable for in vivo applications.⁽¹⁵⁾

9. Controlled Drug Release

Dendrimers provide controlled release of drugs through physical encapsulation or chemical conjugation. The release profile can be adjusted by modifying the surface groups or the dendrimer's generation level, which influences the internal cavity size and branching density.⁽¹⁰⁾

Applications of Unique Properties These properties enable dendrimers to act as carriers for various drugs, including:

Hydrophobic drugs: Encapsulated within the hydrophobic core.

Hydrophilic drugs: Attached to the hydrophilic surface groups.

Nucleic acids and peptides: Delivered through electrostatic interactions with the charged surface.

MECHANISMS OF DRUG DELIVERY BY DENDRIMERS

Dendrimers are versatile carriers that employ various mechanisms to deliver therapeutic agents effectively. Their unique structure, comprising an internal cavity and surface functional groups, allows them to interact with drugs in multiple ways. The mechanisms primarily include encapsulation, surface adsorption, and covalent conjugation, enabling controlled and targeted delivery.

1. Encapsulation of Drugs

Dendrimers can encapsulate drug molecules within their hydrophobic interior through non-covalent interactions such as hydrogen bonding, hydrophobic interactions, and van der Waals forces. This mechanism is particularly useful for:

Hydrophobic drugs: Encapsulation enhances their solubility, stability, and bioavailability.

Protection of drugs: Encapsulation shields drugs from enzymatic degradation, extending their half-life in the body.⁽⁶⁾

For example, hydrophobic drugs like paclitaxel have been successfully encapsulated in dendrimers to improve solubility and therapeutic efficacy.

2. Surface Adsorption or Complexation

Drugs can adsorb onto the dendrimer surface through electrostatic interactions or hydrogen bonding. This mechanism is especially effective for:

Charged molecules: Positively charged dendrimers (e.g., PAMAM dendrimers with terminal amine groups) can interact with negatively charged molecules like DNA or siRNA.

Non-covalent binding: This approach allows reversible binding, which facilitates controlled drug release.⁽¹⁶⁾

For instance, dendrimers have been used to complex with genetic materials like plasmid DNA for gene delivery applications.

3. Covalent Conjugation

Therapeutic agents can be chemically conjugated to the surface functional groups of dendrimers. This covalent attachment ensures:

Stable linkage: Prevents premature drug release during systemic circulation.

Controlled release: Drugs are released in response to specific stimuli such as pH, temperature, or enzymatic activity.

A notable example is the conjugation of methotrexate to dendrimers for targeted cancer therapy, where the drug is released specifically at the tumor site in response to acidic conditions.

4. Targeted Drug Delivery

Dendrimers can be engineered for targeted drug delivery by attaching specific ligands (e.g., folic acid, antibodies, peptides) to their surface. These ligands guide dendrimers to specific tissues or cells through receptor-mediated endocytosis. This mechanism is widely used in cancer therapy to deliver chemotherapeutic agents selectively to tumor cells, minimizing off-target effects.⁽¹⁷⁾

5. Controlled Drug Release

Dendrimers enable controlled release of drugs through:

Encapsulation mechanisms: Drugs are slowly released from the internal cavities over time.

Stimuli-responsive systems: Surface modifications allow drug release in response to specific conditions such as pH, temperature, or light. For example, acidic tumor environments can trigger drug release from pH-sensitive dendrimer systems.⁽¹⁸⁾

Advantages of Dendrimer Drug Delivery Mechanisms

Improved solubility: Encapsulation and adsorption mechanisms enhance the solubility of poorly soluble drugs.

Reduced toxicity: Targeted delivery minimizes systemic toxicity and side effects.

Versatility: Dendrimers can deliver a wide range of drugs, including small molecules, nucleic acids, and peptides.

Controlled release: Allows for sustained therapeutic effects.

TYPES OF DENDRIMERS IN DRUG DELIVERY

Dendrimers are classified based on their composition, functional groups, and applications. Each type has unique properties that make it suitable for specific drug delivery applications. Below are the major types of dendrimers commonly used in drug delivery:

1. Poly(amidoamine) (PAMAM) Dendrimers

Structure and Properties: PAMAM dendrimers are among the most widely studied dendrimers. They consist of an ethylenediamine or ammonia core and amidoamine branching units. Their surface can terminate in functional groups like amine, carboxyl, or hydroxyl groups, allowing for diverse chemical modifications.

Applications in Drug Delivery:

Encapsulation of hydrophobic drugs such as paclitaxel to enhance solubility.

Gene delivery through electrostatic interactions with negatively charged DNA.

Conjugation with targeting ligands for cancer therapy.

Advantages: High biocompatibility, multiple functionalization options, and well-defined structure.⁽¹⁹⁾

2. Polypropylene Imine (PPI) Dendrimers

Structure and Properties: PPI dendrimers are based on a diaminobutane core with polypropylene imine branching units. They have a dense outer shell with primary amines that can interact with drugs or biological molecules.

Applications in Drug Delivery:

Delivery of anticancer drugs by forming complexes with negatively charged molecules.

Encapsulation of hydrophobic drugs in their internal cavities.

Advantages: High stability, efficient drug loading, and ease of surface functionalization. However, their cytotoxicity requires surface modification to improve biocompatibility.⁽¹⁸⁾

3. PEGylated Dendrimers

Structure and Properties: PEGylation involves attaching polyethylene glycol (PEG) chains to the surface of dendrimers. This modification improves the dendrimer's solubility, stability, and circulation time.

Applications in Drug Delivery:

Delivery of anticancer agents, where PEGylation reduces immunogenicity and prolongs circulation in the bloodstream.

Improved targeting efficiency due to reduced protein adsorption (stealth property).

Advantages: Reduced toxicity and enhanced biocompatibility, especially for in vivo applications.⁽²⁰⁾

4. Polyester Dendrimers

Structure and Properties: These dendrimers are synthesized using biodegradable polyester branching units, making them highly biocompatible and suitable for medical applications.

Applications in Drug Delivery:

Delivery of hydrophilic and hydrophobic drugs through encapsulation or conjugation.

Used in stimuli-responsive drug delivery systems for controlled release.

Advantages: Biodegradable and environmentally friendly, with minimal toxicity.⁽¹⁶⁾

5. Chitosan-Based Dendrimers

Structure and Properties: These dendrimers are synthesized using chitosan as a base, a naturally derived polysaccharide with inherent biocompatibility and biodegradability.

Applications in Drug Delivery:

Delivery of nucleic acids for gene therapy.

Used in wound healing and transdermal drug delivery systems.

Advantages: Biocompatibility, antibacterial properties, and mucoadhesion for drug delivery in mucosal tissues.⁽¹⁴⁾

6. Dendritic Polypeptides

Structure and Properties: These dendrimers are composed of amino acid-based branching units, mimicking natural peptides. Their biodegradability and low toxicity make them ideal for biological applications.

Applications in Drug Delivery:

Delivery of peptide-based therapeutics.

Targeted cancer therapy through functionalized surface groups.

Advantages: High specificity and biocompatibility⁽¹⁰⁾

7. Hybrid Dendrimers

Structure and Properties: Hybrid dendrimers combine dendritic structures with other nanomaterials like liposomes,

polymers, or inorganic nanoparticles to enhance their functionality.


Applications in Drug Delivery:

Co-delivery of drugs and imaging agents for theranostic applications.

Stimuli-responsive systems for smart drug release.

Advantages: Enhanced versatility and multifunctionality.⁽²²⁾

Each type of dendrimer offers unique benefits tailored to specific drug delivery needs. PAMAM dendrimers are the most extensively studied, but PEGylated, biodegradable polyester, and hybrid dendrimers are gaining popularity due to their improved safety profiles and enhanced targeting capabilities. The choice of dendrimer depends on the drug's properties, delivery route, and therapeutic objectives.



ADVANTAGES OF DENDRIMERS IN DRUG DELIVERY

Dendrimers offer several unique advantages in drug delivery due to their well-defined nanoscale structure, surface functionality, and high degree of control over their physical and chemical properties. These advantages make them versatile carriers for therapeutic agents across a range of diseases.

1. High Drug-Loading Capacity

Dendrimers provide a high surface-to-volume ratio with multiple functional groups on their surface. This allows the attachment or encapsulation of multiple drug molecules within a single dendrimer structure.

Drugs can either be encapsulated in the internal cavities or conjugated to surface groups, significantly enhancing the drug-loading efficiency compared to conventional nanocarriers.⁽²³⁾

2. Enhanced Solubility

Many poorly water-soluble drugs can be encapsulated within the hydrophobic core of dendrimers, improving their solubility and bioavailability. For example,

paclitaxel and doxorubicin, which have low water solubility, have shown enhanced solubility when loaded into dendrimers.⁽²⁾

3. Biocompatibility and Reduced Toxicity

Surface modifications, such as PEGylation or hydroxylation, improve the biocompatibility of dendrimers. This reduces their cytotoxicity and makes them safer for in vivo applications.

For example, hydroxyl-terminated PAMAM dendrimers exhibit reduced cytotoxicity compared to amine-terminated ones.⁽¹⁶⁾

4. Controlled and Targeted Drug Release

Dendrimers enable controlled release of drugs through physical encapsulation or chemical conjugation. Stimuli-responsive dendrimers can release drugs in response to specific triggers, such as pH, temperature, or enzymes, providing site-specific delivery.

For instance, pH-sensitive dendrimers release drugs in the acidic tumor microenvironment, minimizing off-target effects.⁽⁶⁾

5. Multifunctionality

Dendrimers can be engineered to carry multiple therapeutic agents, targeting ligands, and diagnostic molecules simultaneously. This multifunctionality allows for combined therapeutic and diagnostic applications (theranostics). For example, dendrimers conjugated with anticancer drugs and imaging agents enable real-time monitoring of drug delivery.⁽¹⁸⁾

6. Enhanced Permeation and Retention (EPR) Effect

The nanoscale size of dendrimers (typically 1–10 nm) allows them to accumulate in tumor tissues through the enhanced permeation and retention (EPR) effect. This property is particularly useful for passive targeting of solid tumors.⁽¹⁴⁾

7. Versatility in Drug Delivery Applications

Dendrimers can deliver a wide variety of therapeutic agents, including:

Small molecules: Encapsulation or conjugation for improved solubility and controlled release.

Nucleic acids: Electrostatic interaction with negatively charged DNA or RNA for gene therapy.

Peptides and proteins: Protection against enzymatic degradation during delivery.⁽²¹⁾

8. Scalability and Customizability

Dendrimers can be synthesized in various generations (e.g., G1, G2, etc.), each with a predictable number of branching units and surface groups. This scalability enables precise tuning of their size, drug-loading capacity, and surface properties.⁽⁹⁾

The advantages of dendrimers in drug delivery—ranging from high drug-loading capacity and controlled release to biocompatibility and multifunctionality—make them one of the most promising nanocarrier systems. Their adaptability for delivering diverse therapeutic agents provides significant potential for improving the efficacy and safety of treatments across various medical fields.

APPLICATIONS OF DENDRIMERS IN DRUG DELIVERY

Dendrimers have emerged as a promising nanocarrier for drug delivery due to their unique properties such as nanoscale size, multivalency, and the ability to encapsulate or conjugate drugs. Their applications span across various fields of medicine, enhancing the therapeutic efficacy of drugs, reducing toxicity, and enabling targeted delivery.

1. Cancer Therapy

Targeted Drug Delivery: Dendrimers can be functionalized with ligands such as folic acid, antibodies, or peptides that specifically target cancer cells. For example, folic acid-conjugated dendrimers bind to folate receptors overexpressed on cancer cells, enabling selective delivery of chemotherapeutic drugs like methotrexate.⁽¹⁵⁾

Enhanced Solubility of Drugs: Poorly water-soluble anticancer drugs like paclitaxel can be encapsulated in the

hydrophobic core of dendrimers, improving their solubility and bioavailability.

Multidrug Delivery: Dendrimers can simultaneously deliver multiple drugs or combine drugs with imaging agents for theranostic applications.

2. Gene Delivery

Dendrimers, particularly PAMAM dendrimers, are widely used as non-viral vectors for delivering genetic material such as plasmid DNA, siRNA, and mRNA.

Their positively charged surface facilitates electrostatic interaction with negatively charged DNA or RNA, forming stable complexes for cellular uptake.

Functionalization of dendrimers can reduce toxicity and improve transfection efficiency, making them a safer alternative to viral vectors.

3. Antimicrobial Delivery

Dendrimers have demonstrated antimicrobial activity against bacteria, fungi, and viruses. For example, cationic dendrimers disrupt bacterial cell membranes, leading to cell death. Encapsulation of antibiotics or antifungal agents within dendrimers enhances their efficacy and reduces resistance by controlled release.

Dendrimers functionalized with quaternary ammonium groups or other antimicrobial moieties can be used for wound healing and infection control.

4. Anti-Inflammatory Drug Delivery

Dendrimers are employed to deliver anti-inflammatory drugs such as indomethacin and ibuprofen, improving their solubility and therapeutic effect.

They can be targeted to inflamed tissues using surface modifications, reducing systemic side effects and increasing drug concentration at the site of inflammation.

5. Cardiovascular Therapy

Dendrimers have been used to deliver cardiovascular drugs, such as anticoagulants and anti-hypertensives, for precise and sustained release.

They improve the pharmacokinetics of drugs like heparin, minimizing the need for frequent dosing.

6. Ophthalmic Applications

Dendrimers are utilized in eye drops to enhance the bioavailability and residence time of drugs for treating ocular diseases such as glaucoma, uveitis, and dry eye syndrome.

For instance, dendrimer-based formulations of anti-inflammatory drugs have shown better penetration and prolonged therapeutic effects.⁽²⁴⁾

7. Vaccine Delivery

Dendrimers have been explored as adjuvants or carriers for vaccine delivery. They can enhance the immune response by presenting antigens in a multivalent manner.

For example, dendrimer-based systems have been investigated for delivering peptide vaccines against infectious diseases and cancer.⁽²⁵⁾

Dendrimers have revolutionized drug delivery by providing customizable, efficient, and targeted systems for various

therapeutic applications. Their ability to enhance solubility, control drug release, and reduce systemic toxicity makes them invaluable in modern medicine. Continued research and clinical trials are expected to expand their potential, particularly in precision medicine and nanotheranostics.

List of Commercially Available Dendrimers and Dendrimer Based Product

Product Name	Dendrimer Type	Application	Manufacturer	Remarks	Reference
VivaGel®	SPL7013 (PAMAM derivative)	Antiviral gel for HIV and HSV prevention	Starpharma Holdings Ltd.	Approved for use as a microbicide and as a coating for condoms.	(26)
AdvaCare®	PAMAM	Diagnostic imaging	Dendritic Nanotechnologies	Used for MRI contrast enhancement.	(27)
Priostar®	Polylysine-based dendrimer	Drug delivery and diagnostics	Starpharma Holdings Ltd.	Offers tunable surface properties for various applications.	(28)
Stratus® CS	PAMAM	Diagnostics (cardiac markers)	Abbott Laboratories	Utilized in cardiac diagnostics for rapid response.	(29)
DEP® Docetaxel	PEGylated dendrimer	Oncology (cancer treatment)	Starpharma Holdings Ltd.	In clinical trials for targeted cancer therapy.	(30)
Alert Ticket®	PAMAM	Biosensors and diagnostics	DNT (The Dow Chemical Co.)	Utilized for detecting toxic agents in security applications.	(31)
SuperFect®	PAMAM	Gene delivery	Qiagen	A transfection reagent for gene delivery in cell cultures.	(32)
Vivagel® BV	SPL7013 (PAMAM derivative)	Treatment for bacterial vaginosis	Starpharma Holdings Ltd.	Approved as a topical treatment for bacterial vaginosis.	(26)

FUTURE PROSPECTIVE:

Dendrimers hold immense potential in revolutionizing drug delivery systems, and their future prospects are highly promising. Advancements in dendrimer synthesis and functionalization are expected to overcome current challenges such as toxicity, biocompatibility, and scalability. Research into biodegradable dendrimers could further enhance their safety profile, making them more suitable for clinical applications.

The integration of dendrimers with emerging technologies like CRISPR, RNA therapeutics, and nanobots may unlock new frontiers in gene editing and precision medicine. Moreover, their use in theranostics, combining therapeutic and diagnostic capabilities, could pave the way for real-time monitoring and treatment of diseases. The development of cost-effective production methods and alignment with regulatory guidelines will also play a critical role in their commercialization.

In the coming years, dendrimers are likely to find extensive applications in personalized medicine, targeted cancer

therapy, vaccine delivery, and advanced treatments for neurological and genetic disorders, solidifying their position as a cornerstone of next-generation drug delivery systems.

CONCLUSION:

Dendrimers are emerging as a promising nanocarrier system in drug delivery due to their unique structure, tunable size, and multivalency. They provide enhanced drug solubility, controlled release, targeted delivery, and reduced toxicity compared to traditional systems. Their surface functionalization allows precise drug conjugation and selective targeting of diseased cells, such as in cancer therapy. Furthermore, dendrimers have shown potential in delivering genes, peptides, and vaccines. Despite these advantages, challenges like biocompatibility, high production costs, and regulatory hurdles need to be addressed for widespread clinical use. Continued research and technological advancements may establish dendrimers as a versatile platform for effective and innovative drug delivery solutions.

REFERENCES

1. Tomalia DA, Baker H, Dewald J, et al. A new class of polymers: starburst-dendritic macromolecules. *Polym J*. 1985; 17(1):117–132.
2. Chauhan AS. Dendrimers for drug delivery. *Mol Pharm*. 2018; 15(10):4561–4576.
3. Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. *Nanoscale Res Lett*. 2014; 9:247.
4. Sharma A, Kaur G, Mittal A. Dendrimers: a potential carrier for targeted drug delivery. *Int J Pharm Investig*. 2016;6(1):1–9.
5. Gupta U, Agashe HB, Asthana A, Jain NK. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. *Biomaterials*. 2006; 27(21):4388–4399.
6. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. *Adv Drug Deliv Rev*. 2005; 57(15):2106–2129.
7. Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, properties, and applications. *Chem Rev*. 1999; 99(7):1665–1688.
8. Tomalia DA, Naylor AM, Goddard WA. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. *Angew Chem Int Ed Engl*. 1990; 29(2):138–175.
9. Lee CC, MacKay JA, Fréchet JM, Szoka FC. Designing dendrimers for biological applications. *Nat Biotechnol*. 2005; 23(12):1517–1526.
10. Klajnert B, Bryszewska M. Dendrimers: properties and applications. *Acta Biochim Pol*. 2001;48(1):199–208.
11. Newkome GR, Yao ZQ, Baker GR, Gupta VK. Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol. *J Org Chem*. 1985;50(11):2003–2004.
12. Frechet JM, Tomalia DA. Dendrimers and other dendritic polymers: concepts and applications. *Nature*. 2002; 409(6818):1027–1031.
13. Jain NK, Gupta U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. *Nanomedicine*. 2008;4(3):302–317.
14. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. *Adv Drug Deliv Rev*. 2005;57(15):2215–2237.
15. Majoros IJ, Myc A, Thomas TP, et al. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. *Biomacromolecules*. 2006;7(2):572–579.
16. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. *Prog Polym Sci*. 2014;39(2):268–307.
17. Choi Y, Thomas T, Kotlyar A, et al. Synthesis and functional evaluation of DNA-assembled dendrimer clusters for cancer cell-specific targeting. *Chem Biol*. 2005;12(1):35–43.
18. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. *Drug Discov Today*. 2005;10(1):35–43.
19. Tomalia DA, Frechet JM. Dendrimers: a new class of polymers. *Chem Eng News*. 1991;69(1):40–45.
20. Newkome GR, Yao Z, Baker GR, Gupta VK. Cascade molecules: a new approach to micelles. *J Org Chem*. 1985;50(11):2003–2004.
21. Kukowska-Latallo JF, Bielinska AU, Johnson J, et al. Efficient transfer of genetic material into mammalian cells using Starburst PAMAM dendrimers. *Proc Natl Acad Sci USA*. 1996;93(10):4897–4902.
22. Majoros IJ, Thomas TP, Mehta CB, Baker JR Jr. PAMAM dendrimer-based multifunctional conjugate for cancer therapy. *J Med Chem*. 2005;48(23):5892–5899.
23. Patri AK, Majoros IJ, Baker JR Jr. Dendritic polymer macromolecular carriers for drug delivery. *Curr Opin Chem Biol*. 2002;6(4):466–471.
24. Yavuz B, Pehlivan SB, Ünlü N. Dendrimeric systems and their applications in ocular drug delivery. *Sci World J*. 2013;2013:732340.
25. Jain NK, Kesharwani P, Gupta U. Dendrimer toxicity: let's meet the challenge. *Int J Pharm*. 2010;394(1–2):122–142.
10. Tyler, M. J., et al. (2016). "Applications of dendrimers in nanomedicine." *Journal of Drug Delivery Science and Technology*.
11. Cheng, Y., et al. (2008). "Dendrimers as carriers for MRI contrast agents." *Advanced Drug Delivery Reviews*.
12. Malik, N., et al. (2005). "Polylysine dendrimers: a versatile drug delivery system." *International Journal of Pharmaceutics*.
13. Abbott Diagnostics (2020). "Stratus® CS Analyzer Product Overview." Retrieved from the Abbott website.
14. Starpharma Holdings (2022). "Dendrimer-based oncology pipeline." Retrieved from Starpharma's official site.
15. Gupta, U., et al. (2010). "Dendrimers in biosensor development." *Biosensors and Bioelectronics*.
16. Qiagen (2021). "SuperFect® Transfection Reagent Data Sheet." Retrieved from Qiagen's website.